The Soluble Epoxide Hydrolase Inhibitor AR9281 Decreases Blood Pressure, Ameliorates Renal Injury and Improves Vascular Function in Hypertension

Soluble epoxide hydrolase inhibitors (sEHIs) are demonstrating promise as potential pharmaceutical agents for the treatment of cardiovascular disease, diabetes, inflammation, and kidney disease. The present study determined the ability of a first-in-class sEHI, AR9281, to decrease blood pressure, im...

Descripción completa

Detalles Bibliográficos
Autores principales: Imig, John D., Carpenter, Margaret A., Shaw, Sean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International 2009
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978544/
https://www.ncbi.nlm.nih.gov/pubmed/27713235
http://dx.doi.org/10.3390/ph2030217

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3978544/
https://www.ncbi.nlm.nih.gov/pubmed/27713235
http://dx.doi.org/10.3390/ph2030217

Ejemplares similares